Journal profile · Pharmacology & Pharmacy
Current Pharmaceutical Analysis
ISSN 1573-4129 · eISSN 1875-676X · Bentham Science Publishers B.V. · U ARAB EMIRATES · Quarterly · Founded 2005
Current Pharmaceutical Analysis: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.59; hybrid open access; APC about USD 2,100; review about 2 months (community reports); community-reported acceptance: about 50%; 57 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Current Pharmaceutical Analysis is published by Bentham Science Publishers B.V. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Analytical Methods in Pharmaceuticals, Analytical Chemistry and Chromatography and Antibiotics Pharmacokinetics and Efficacy, together about 47.8% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Volumes 1-20 of Current Pharmaceutical Analysis, published by Bentham Science, can be accessed here: https://www.benthamscience.com/journal/cpa. Current Pharmaceutical Analysis publishes full-length/mini reviews and original research articles on all the most recent advances in pharmaceutical and biomedical analysis. All aspects of the field are represented including drug analysis and pharmacological research. The journal is essential to all involved in pharmaceutical, biochemical, biomedicine and clinical analysis.This journal contains four sections:Section A (Pharmaceutical Science): This section focuses on the discovery, development, evaluation, and regulation of medications and therapies. Its main goal is to enhance human health by developing new pharmaceutical products, refining drug delivery methods, and ensuring both the safety and effectiveness of treatments.Section B (Toxicology and Pharmaceutics): This section focuses on the formulation, development, and toxicology response of drugs. It encompasses the design and testing of drug delivery systems to ensure optimal absorption, distribution, effectiveness and toxicity of medications in the body.Section C (Pharmaceutical Biotechnology): This section focuses on the utilizing biological systems, processes, or organisms to create drugs and treatments. It encompasses the development of biopharmaceuticals, including vaccines, monoclonal antibodies, gene therapies, and bionanotechnology. Additionally, it involves the application of bioengineering methods to alter cells and microorganisms for therapeutic applications.Section D (Drug Discovery): This section focuses on the identification, design, and development of new pharmaceutical compounds aimed at treating various diseases. It involves investigating novel chemical entities, natural substances, and biological molecules, utilizing methods such as high-throughput screening, molecular modeling, and structure-based drug design. The main goal is to discover safe, effective, and targeted treatments by comprehending disease mechanisms and refining lead compounds through preclinical evaluation.Editorial Board
From the journal's Aims & Scope
Research area (LetPub): Pharmacology & Pharmacy
Main research topics OpenAlex counts of recent articles; shares are approximate
- Analytical Methods in PharmaceuticalsChemistry21.7%
- Analytical Chemistry and ChromatographyChemistry20.6%
- Antibiotics Pharmacokinetics and EfficacyMedicine5.6%
- Electrochemical sensors and biosensorsEngineering4.2%
- Computational Drug Discovery MethodsComputer Science3.9%
- Pesticide Residue Analysis and SafetyAgricultural and Biological Sciences3.4%
- Traditional Chinese Medicine AnalysisMedicine3.3%
- Metabolomics and Mass Spectrometry StudiesBiochemistry, Genetics and Molecular Biology3.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.59LetPub ·
- Impact factor (publisher) 2025
- 3.6Publisher website ·
- CiteScore 2026-06
- 2.7LetPub ·
- SJR 2026-06
- 0.44LetPub ·
- SNIP 2026-06
- 0.47LetPub ·
- h-index
- 22LetPub ·
- h-index
- 35OpenAlex ·
- i10-index
- 241OpenAlex ·
- 2-year mean citedness
- 4.06OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 23.96%LetPub ·
Volume
- Articles per year
- 40LetPub ·
Articles by year OpenAlex count · 1,377 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 68 | 68 | 15 |
| 2025 | 57 | 56 | 189 |
| 2024 | 93 | 11 | 681 |
| 2023 | 51 | 2 | 243 |
| 2022 | 53 | 4 | 242 |
| 2021 | 54 | 4 | 195 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
Too few articlesOnly 7 articles from the last 24 months carry both submission and acceptance dates, too few for a median
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 2 monthsLetPub ·
- Average acceptance (community reports)
- 50%LetPub ·
- Acceptance rate (publisher)
- 23%Publisher website ·
- Submission to first decision
- 4 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 2,100 | — | — | |
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare1 items from the author guidelines
- Abstract
- ≤ 300 words
Article types accepted10, with length limits
- commentaryCommentary Expert opinions on published works or the current state of a field, including references. 800–3000 words, no abstract in the main textLength not stated
- correspondenceCorrespondence A letter or reply sent to the journal to raise points of interest, discuss differing opinions, or encourage participation 800–3000 words, no abst…Length not stated
- editorialEditorial An overview or opinion on a particular issue conveyed by an editor or someone invited by the editor 800–3000 words, no abstract in the main textLength not stated
- full length articleFull Length Article A report on new research findings or conceptual analysis that makes a significant contribution to knowledge 4000–8000 wordsLength not stated
- letterArticle TypeDescriptionLengthFull Length ArticleA report on new research findings or conceptual analysis that makes a significant contribution to knowledge4000–…Length not stated
- letter to the editorArticle TypeDescriptionLengthFull Length ArticleA report on new research findings or conceptual analysis that makes a significant contribution to knowledge4000–…Length not stated
- opinionArticle TypeDescriptionLengthFull Length ArticleA report on new research findings or conceptual analysis that makes a significant contribution to knowledge4000–…main text ≤ 12,000 words
- research reportArticle TypeDescriptionLengthFull Length ArticleA report on new research findings or conceptual analysis that makes a significant contribution to knowledge4000–…Length not stated
- review articleReview Article An overview of the development of a field or current thinking. It integrates multiple sources of information and includes many citations. It emph…Length not stated
- short communicationShort Communication A concise format for observations and research reports. 1500–3000 wordsLength not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright Creative Commons Attribution (CC BY)
Allows users to: distribute and copy the article; create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation); include in a collective work (such as an anthology); and text or data mine the article. These uses are permitted even for commercial purposes, provided the user: gives appropriate credit to the author(s) (with a lin…
Source ↗Publisher website ·- Open access KeAi Guide for authors: Open Access
Open access Model summary
This is an open access journal: all articles will be immediately and permanently free for everyone to read and download. To provide open access, this journal has an open access fee (also known as an article publishing charge APC) which needs to be paid by the authors or on their behalf e.g. by their research funder or institution. Permitted third party (re)use is defined by the following Creative …
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors to determine suitability for publication in this journal. If your submission is deemed suitable, it will typically be sent to a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected will…
Source ↗Publisher website ·- Preprints Preprint sharing
Authors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Bentham Science Publishers B.V.
- Country or region
- U ARAB EMIRATES
- Language
- English
- Frequency
- Quarterly
- Founded
- 2005
- ISSN
- 1573-4129
- Electronic ISSN
- 1875-676X
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
FAQ
Frequently asked questions about Current Pharmaceutical Analysis
What CAS zone is Current Pharmaceutical Analysis in?
In the 2025 upgraded edition of the CAS Journal Ranking, Current Pharmaceutical Analysis is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Current Pharmaceutical Analysis?
The latest impact factor listed by LetPub is 3.59; CiteScore 2.7, h-index 35.
How long does peer review take at Current Pharmaceutical Analysis?
Authors report an average review time of about 2 months; the community-reported acceptance is “about 50%”; the journal's website gives an acceptance rate of 23%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Current Pharmaceutical Analysis?
According to LetPub and DOAJ records, Current Pharmaceutical Analysis is indexed in SCIE and Scopus.
Is Current Pharmaceutical Analysis open access, and what is the APC?
Current Pharmaceutical Analysis is a hybrid journal. For open-access publication: APC about USD 2,100.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .